-
公开(公告)号：WO2022140344A1
公开(公告)日：2022-06-30
申请号：PCT/US2021/064546
申请日：2021-12-21
Applicant: AMGEN INC.
Inventor： TAN, Glenn, Christopher , ZASADZINSKA, Ewelina , HOFFMANN, Patrick , WU, Bin
IPC: C12N5/00 , B01L3/00 , C12M1/00 , G01N21/64 , B01L2200/0668 , B01L2300/0896 , C12N5/0075
Abstract: The present disclosure provides materials and methods identifying, selecting, and characterizing cells that express and secrete non-Fc containing biomolecules.
-
公开(公告)号：WO2017021354A1
公开(公告)日：2017-02-09
申请号：PCT/EP2016/068294
申请日：2016-08-01
Applicant: AMGEN RESEARCH (MUNICH) GMBH , AMGEN INC.
Inventor： RAUM, Tobias , DEISTING, Wibke , BLUEMEL, Claudia , PANZER, Marc , HOFFMANN, Patrick , NAHRWOLD, Elisabeth , NOLAN-STEVAUX, Olivier , LUTTERBUESE, Ralf
CPC classification number: C07K16/2875 , C07K16/2809 , C07K16/3069 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/64 , C07K2317/73 , C07K2317/92 , C07K2317/94
Abstract: The present disclosure relates to a bispecific antibody construct comprising a first binding domain which binds to human CD70 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the disclosure provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the disclosure provides a process for the production of the antibody construct of the disclosure, a medical use of said antibody construct and a kit comprising said antibody construct.
Abstract translation: 本公开涉及双特异性抗体构建体，其包含与靶细胞表面上的人CD70结合的第一结合结构域和与T细胞表面上的人CD3结合的第二结合结构域。 此外，本公开提供编码抗体构建体的多核苷酸，包含所述多核苷酸的载体和用所述多核苷酸或载体转化或转染的宿主细胞。 此外，本公开提供了制备本公开的抗体构建体的方法，所述抗体构建体的医学用途和包含所述抗体构建体的试剂盒。
-
公开(公告)号：WO2014114800A1
公开(公告)日：2014-07-31
申请号：PCT/EP2014/051550
申请日：2014-01-27
Applicant: AMGEN RESEARCH (MUNICH) GMBH , AMGEN INC.
Inventor： XIAO, Shouhua , PAN, Zheng , WICKRAMASINGHE, Dineli , JEFFRIES, Shawn M. , KING, Chadwick Terence , CHAN, Brian Mingtung , KUFER, Peter , LUTTERBUESE, Ralf , RAUM, Tobias , HOFFMANN, Patrick , RAU, Doris , KISCHEL, Roman , LEMON, Bryan , WESCHE, Holger
CPC classification number: C07K16/2809 , A61K47/60 , A61K2039/505 , C07K16/28 , C07K16/2896 , C07K16/3053 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/626 , C07K2317/73 , C07K2317/77 , C07K2317/92 , C07K2319/00
Abstract: The present invention provides to a antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention relates to a nucleic acid sequence encoding the antibody construct, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention relates a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
Abstract translation: 本发明提供了一种抗体构建物，其包含能够结合靶细胞表面上的人CDH19的第一人结合结构域和能够结合T细胞表面上的人CD3的第二结构域。 此外，本发明涉及编码抗体构建体的核酸序列，包含所述核酸序列的载体和用所述载体转化或转染的宿主细胞。 此外，本发明涉及制备本发明的抗体构建体的方法，所述抗体构建体的医学用途和包含所述抗体构建体的试剂盒。
-
Patent Agency Ranking
公开(公告)号：WO2022096698A1
公开(公告)日：2022-05-12
申请号：PCT/EP2021/080859
申请日：2021-11-08
Applicant: AMGEN INC. , AMGEN RESEARCH (MUNICH) GMBH
Inventor： RAU, Doris , RAUM, Tobias , HOFFMANN, Patrick , MUENZ, Markus , KLINGER, Matthias , NAEGELE, Virgine , WINKEL, Lisa , GHATTYVENKATAKRISHNA, Pavan , HUH, Joon Hoi , MCAULEY, Arnold , KANAPURAM, Sekhar
Abstract: The invention relates to a polypeptide or polypeptide construct comprising: a binding domain binding to an extracellular epitope of the human CD3s chain comprising or consisting of a VH region and a VL region, wherein i) the VH region comprises: a CDR- H1 sequence of X1YAX2N, where X1 is K, V, S, G, R, T, or I; and X2 is M or I; a CDR-H2 sequence of RIRSKYNNYATYYADX1VKX2, where Χ1 is S or Q; and X2 is D, G, K, S, or E; and a CDR-H3 sequence of HX1NFGNSYX2SX3X4AY, where ΧΊ is G, R, or A; X2 is I, L, V, or T; X3 is Y, W or F; and X4 is W, F or Y; and ii) wherein the VL region comprises: a CDR-L1 sequence of ΧΊ SSTGAVTX2X3X4YX5N, where ΧΊ is G, R, or A; X2 is S or T; X3 is G or S; X4 is N or Y; and X5 is P or A; a CDR-L2 sequence of X1TX2X3X4X5X6; where Χ1 is G or A; X2 is K, D, or N; X3 is F, M or K; X4 is L or R; X5 is A, P, or V; and X6 is P or S; and a CDR-L3 sequence of X1LWYSNX2VW, where X1 is V, A, or T; and X2 is R or L; and iii) wherein one or more of CDR sequences of the VH region of i) and/or of the VL region of ii) comprise one amino acid substitution or a combination thereof selected from X24V and X24F in CDR-H1; D15, and X116A in CDR-H2; H1, X12E, F4, and N6 in CDR-H3; and X11L and W3 in CDR-L3. The invention also relates to a polynucleotide encoding the polypeptide or polypeptide construct of the invention, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or with said vector. Moreover, the invention also provides for a process for the production of said polypeptide or polypeptide construct and a pharmaceutical composition comprising said polypeptide or polypeptide construct of the invention. Furthermore, the invention relates to medical uses of said polypeptide or polypeptide construct and kits comprising said polypeptide or polypeptide construct.
-
公开(公告)号：WO2017134134A1
公开(公告)日：2017-08-10
申请号：PCT/EP2017/052202
申请日：2017-02-02
Applicant: AMGEN RESEARCH (MUNICH) GMBH , AMGEN INC.
Inventor： RAUM, Tobias , MUENZ, Markus , BROZY, Johannes , KUFER, Peter , HOFFMANN, Patrick , FRIEDRICH, Matthias , RATTEL, Benno , BOGNER, Pamela , WOLF, Andreas , POMPE, Cornelius
IPC: C07K16/28
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2809 , C07K2317/31 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2317/64 , C07K2317/94 , C07K2319/00
Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or the Macaca CD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
Abstract translation: 本发明提供了特异性Fc模式的双特异性抗体构建体，其特征在于包含与BCMA结合的第一结构域，与人和/或猕猴CD3ε链的细胞外表位结合的第二结构域和 第三个领域，这是特定的Fc模式。 此外，本发明提供了编码抗体构建体的多核苷酸，包含该多核苷酸的载体，表达构建体的宿主细胞以及包含其的药物组合物。
-
公开(公告)号：WO2016016412A1
公开(公告)日：2016-02-04
申请号：PCT/EP2015/067610
申请日：2015-07-31
Applicant: AMGEN RESEARCH (MUNICH) GMBH , AMGEN INC.
Inventor： KUFER, Peter , HOFFMANN, Patrick , RAUM, Tobias , LUTTERBUESE, Ralf , NAHRWOLD, Elisabeth , BLUMEL, Claudia , XIAO, Shouhua , PAN, Zheng , WICKRAMASINGHE, Dineli
CPC classification number: C07K16/468 , A61K47/60 , A61K2039/505 , C07K16/28 , C07K16/2809 , C07K16/2896 , C07K16/30 , C07K2317/21 , C07K2317/30 , C07K2317/31 , C07K2317/33 , C07K2317/622 , C07K2317/73 , C07K2319/00
Abstract: The present invention provides to a bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
Abstract translation: 本发明提供了双特异性抗体构建体，其包含与靶细胞表面上的人CDH19结合的第一人结合结构域和与T细胞表面上的人CD3结合的第二结合结构域。 此外，本发明提供编码抗体构建体的多核苷酸，包含所述多核苷酸的载体和用所述多核苷酸或载体转化或转染的宿主细胞。 此外，本发明提供了制备本发明的抗体构建体的方法，所述抗体构建体的医学用途和包含所述抗体构建体的试剂盒。
-
公开(公告)号：WO2021089748A2
公开(公告)日：2021-05-14
申请号：PCT/EP2020/081224
申请日：2020-11-06
Applicant: AMGEN RESEARCH (MUNICH) GMBH , AMGEN INC.
Inventor： ANLAHR, Jonas , ARVEDSON, Tara , BAILIS, Julie , CHUN, Matthew , D'ANGELO, Igor , DAHLHOFF, Christoph , EVERTS, Stephanie , FRIEDRICH, Matthias , GAEDTKE, Lars , HOFFMANN, Patrick , GOLDSTEIN, Rebecca , HONER, Jonas Karl-Josef , KISCHEL, Roman , KLINGER, Matthias , KUFER, Peter , MUENZ, Markus , NAEGELE, Virginie , PANZER, Marc , RAU, Doris , RAUM, Tobias , ULLRICH, Ines
IPC: C07K16/28 , C07K16/30 , C07K16/2803 , C07K16/2809 , C07K16/2851 , C07K16/2863 , C07K16/2878 , C07K16/2887 , C07K2317/31 , C07K2317/33 , C07K2317/60 , C07K2317/622 , C07K2317/626 , C07K2317/64 , C07K2317/73 , C07K2317/92 , C07K2317/94
Abstract: The present invention provides bispecific antigen-binding molecules characterized by comprising a first and a second domain, each binding to any of CS1, BCMA, CD20, CD22, FLT3, CD123, CLL1, MSLN, CDH3 or EpCAM, a third domain binding to an extracellular epitope of the human and the Macaca CD3ε chain and optionally a fourth domain, which is a Fc modality. Moreover, the invention provides a polynucleotide, encoding the antigen-binding molecule, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
-
8.发明申请
公开(公告)号：WO2017021356A1
公开(公告)日：2017-02-09
申请号：PCT/EP2016/068304
申请日：2016-08-01
Applicant: AMGEN RESEARCH (MUNICH) GMBH , AMGEN INC.
Inventor： RAUM, Tobias , KUFER, Peter , RAU, Doris , ANLAHR, Jonas , BLUEMEL, Claudia , HOFFMANN, Patrick , NAHRWOLD, Elisabeth , BAILIS, Julie
CPC classification number: C07K16/28 , C07K16/2809 , C07K16/30 , C07K2317/31 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2317/94
Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human MSLN on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
Abstract translation: 本发明涉及双特异性抗体构建体，其包含与靶细胞表面上的人MSLN结合的第一结合结构域和与T细胞表面上的人CD3结合的第二结合结构域。 此外，本发明提供编码抗体构建体的多核苷酸，包含所述多核苷酸的载体和用所述多核苷酸或载体转化或转染的宿主细胞。 此外，本发明提供了制备本发明的抗体构建体的方法，所述抗体构建体的医学用途和包含所述抗体构建体的试剂盒。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.028 seconds)
